Migraine and Headache Disorders

Migraine and headache disorders represent a spectrum of neurological conditions that affect brain pain-processing pathways, trigeminal nerve networks, and vascular regulation. This page covers the principal classifications, underlying mechanisms, clinical presentations, and the diagnostic and treatment decision points that distinguish one headache type from another. Headache disorders are among the most prevalent neurological diagnoses in the United States, with migraine alone affecting approximately 39 million people in the US according to the Migraine Research Foundation. Understanding these distinctions matters because misclassification drives ineffective treatment and delays appropriate neurological care.

Definition and Scope

The International Headache Society (IHS) publishes the International Classification of Headache Disorders (ICHD), now in its third edition (ICHD-3), which serves as the global diagnostic standard for all headache conditions. The ICHD-3 organizes headache disorders into two primary categories:

Primary headache disorders — conditions in which the headache itself is the disease, with no identifiable underlying structural or systemic cause
Secondary headache disorders — headaches attributable to another condition such as intracranial hemorrhage, infection, medication overuse, or hypertensive crisis

Primary headache disorders include migraine (with and without aura), tension-type headache, trigeminal autonomic cephalalgias (TACs), and a fourth group of "other primary headaches." Secondary headaches, while less prevalent, carry greater urgency because they may signal life-threatening pathology.

The World Health Organization classifies headache disorders among the most disabling conditions worldwide. Tension-type headache is estimated to affect 40 percent of the global population at some point, while cluster headache — the most severe TAC — affects roughly 1 in 1,000 people and strikes men at a rate approximately 3 times higher than women (ICHD-3 epidemiological notes).

The scope of neurological involvement varies by subtype. Migraine engages cortical spreading depression, trigeminovascular activation, and brainstem pain modulation. Tension-type headache involves pericranial myofascial tenderness without the neurovascular component. Cluster headache activates the posterior hypothalamus and parasympathetic outflow through the sphenopalatine ganglion. The regulatory and diagnostic frameworks governing care for these conditions are covered in depth at Regulatory Context for Neurological Conditions.

How It Works

Migraine Pathophysiology

Migraine involves a cascade beginning in genetically sensitized brains. Cortical spreading depression (CSD) — a wave of neuronal and glial depolarization moving at 3–5 mm per minute across the cortex — is the electrophysiological event underlying migraine aura, as established by research documented in publications of the National Institute of Neurological Disorders and Stroke (NINDS).

CSD activates the trigeminal nerve's ophthalmic branch, releasing neuropeptides including calcitonin gene-related peptide (CGRP). Elevated CGRP causes meningeal vasodilation and dural plasma extravasation, generating the throbbing, unilateral pain characteristic of migraine. Central sensitization follows, explaining cutaneous allodynia (pain from normally non-painful stimuli) reported by a substantial portion of migraine sufferers during attacks.

Tension-Type Headache Mechanism

Tension-type headache lacks the neurovascular signature of migraine. The mechanism centers on peripheral sensitization of pericranial myofascial tissues and, in chronic forms, central sensitization of supraspinal pain pathways. Nitric oxide may play a role in maintaining central sensitization in chronic tension-type headache (ICHD-3 commentary).

Trigeminal Autonomic Cephalalgias

TACs are characterized by unilateral trigeminal pain combined with ipsilateral cranial autonomic features — lacrimation, nasal congestion, ptosis, or conjunctival injection. Cluster headache attacks last 15–180 minutes and occur up to 8 times per day in episodic cycles. The hypothalamic clock-like periodicity of cluster headache — attacks often occurring at the same hour each day — reflects hypothalamic involvement confirmed by positron emission tomography studies cited in ICHD-3.

Common Scenarios

The following presentations represent the most frequently encountered headache disorder profiles in outpatient and emergency neurological settings:

Episodic migraine without aura — Attacks lasting 4–72 hours, unilateral pulsating pain of moderate-to-severe intensity, accompanied by nausea or photophobia/phonophobia. Diagnosis requires at least 5 lifetime attacks meeting ICHD-3 criteria.
Migraine with aura — Visual scotoma, scintillating arc, sensory or speech disturbance preceding or accompanying headache. Aura symptoms develop over 5 or more minutes and each phase lasts fewer than 60 minutes per ICHD-3 criteria.
Chronic migraine — Headache on 15 or more days per month for more than 3 months, with migraine features on at least 8 of those days (ICHD-3, §1.3).
Medication overuse headache (MOH) — A secondary disorder arising from intake of acute headache medications on 10 or more days per month (for triptans or opioids) or 15 or more days per month (for simple analgesics). Recognized by ICHD-3 as a distinct entity requiring withdrawal as primary treatment.
Cluster headache — Orbital or periorbital pain of excruciating severity, strictly unilateral, with ipsilateral autonomic signs, occurring in cyclical bouts.
New daily persistent headache (NDPH) — Headache present continuously from a distinct onset date, typically recalled precisely by the patient, persisting beyond 3 months.

For guidance on when headache patterns warrant urgent neurological evaluation, the resource on persistent headaches and warning signs details red-flag criteria.

Decision Boundaries

Distinguishing primary from secondary headache disorders, and one primary type from another, determines both treatment selection and urgency of workup. The following structured framework reflects ICHD-3 diagnostic logic and NINDS clinical guidance:

Step 1 — Rule out secondary causes
Red-flag features requiring immediate evaluation include: thunderclap onset (peak pain within 60 seconds), fever with neck stiffness, new headache in a patient older than 50, headache with focal neurologic deficit, or progressive worsening without remission. These features trigger imaging and, if indicated, lumbar puncture before any primary diagnosis is assigned.

Step 2 — Establish attack frequency and duration
- Duration under 4 hours with autonomic features → evaluate for TAC subtypes
- Duration 4–72 hours with nausea/photo-phonophobia → evaluate for migraine
- Duration 30 minutes to 7 days, bilateral, non-pulsating, without autonomic features → evaluate for tension-type headache

Step 3 — Assess aura presence and morphology
Aura lasting longer than 60 minutes, or aura with motor weakness, falls into distinct ICHD-3 subcategories (hemiplegic migraine, migraine with brainstem aura) requiring specialist evaluation and specific medication restrictions — notably, triptans are contraindicated in hemiplegic migraine and migraine with brainstem aura per prescribing guidance from the US Food and Drug Administration (FDA).

Step 4 — Identify medication overuse
Before classifying any frequent headache as chronic migraine or chronic tension-type headache, medication use frequency must be quantified against ICHD-3 MOH thresholds. Withdrawal management is a prerequisite to accurate reclassification.

Step 5 — Differentiate episodic from chronic
The 15-day-per-month threshold separates episodic from chronic subtypes for both migraine and tension-type headache. Crossing this threshold changes both the indicated preventive treatment class and the disability classification under tools such as the MIDAS (Migraine Disability Assessment) scale, referenced in clinical practice guidance from the American Academy of Neurology (AAN).

For patients navigating life with frequent migraine episodes, the resource on coping with chronic migraine provides a framework for daily management considerations. A broader map of neurological conditions and their relationships is available at the site index.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)